MediWound Ltd. (MDWD) Scheduled to Post Quarterly Earnings on Thursday
MediWound Ltd. (NASDAQ:MDWD) is scheduled to announce its earnings results before the market opens on Thursday, November 16th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter.
Shares of MediWound Ltd. (NASDAQ MDWD) opened at $4.57 on Monday. MediWound Ltd. has a 1-year low of $4.25 and a 1-year high of $8.25.
A number of equities research analysts recently commented on MDWD shares. Jefferies Group LLC reiterated a “buy” rating and set a $10.00 price target on shares of MediWound in a report on Thursday, September 28th. Oppenheimer Holdings, Inc. reiterated a “buy” rating and set a $10.00 price target on shares of MediWound in a report on Monday, September 18th. Zacks Investment Research upgraded shares of MediWound from a “hold” rating to a “buy” rating and set a $5.75 price objective for the company in a report on Wednesday, October 4th. Cowen and Company assumed coverage on shares of MediWound in a report on Thursday, September 28th. They issued an “outperform” rating and a $9.00 price objective for the company. Finally, ValuEngine upgraded shares of MediWound from a “strong sell” rating to a “sell” rating in a report on Friday, October 20th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. MediWound presently has an average rating of “Buy” and an average target price of $9.15.
TRADEMARK VIOLATION WARNING: This story was published by Watch List News and is owned by of Watch List News. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://www.watchlistnews.com/mediwound-ltd-mdwd-scheduled-to-post-quarterly-earnings-on-thursday/1699698.html.
MediWound Company Profile
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.